AL-S Pharma's AP-101 Shows Promising Survival Benefits in Phase 2 ALS Trial, Advancing to Phase 3
Key Insights
AL-S Pharma (search)'s Phase 2 trial of AP-101, an investigational antibody targeting misfolded SOD1 (search), met its primary safety endpoint and demonstrated prolonged survival and delayed ventilatory support in ALS (search) patients.
The study showed statistically significant treatment effects in both sporadic ALS (search) patients (p = 0.013) and SOD1 (search) mutation carriers (p = 0.036) across 73 participants.
AP-101 reduced functional decline and improved neurofilament biomarkers in patients with elevated misfolded SOD1 (search), supporting its potential as a disease-modifying therapy.
AL-S Pharma (search) announced positive results from its Phase 2 clinical trial of AP-101, an investigational human antibody therapeutic targeting misfolded superoxide dismutase 1 (SOD1 (search)) for the treatment of amyotrophic lateral sclerosis (search) (ALS (search)). The results were presented at the 36th International Symposium on ALS/MND in San Diego, showing the therapy prolonged survival and delayed the need for ventilatory support in ALS patients.
Phase 2 Trial Results Demonstrate Clinical Benefit
The global, randomized, double-blind, placebo-controlled study enrolled 73 participants and successfully met its primary endpoint related to safety and tolerability. Adverse events were comparable to placebo, and no AP-101-induced antibody responses were reported during the trial period.
Analysis of an exploratory composite endpoint revealed that early treatment with AP-101 prolonged survival and delayed ventilatory support compared to study participants who received placebo for six months followed by six months of AP-101 treatment. The therapy demonstrated positive treatment effects in both the sporadic ALS (search) cohort (p = 0.013) and the SOD1 (search) mutation carrier cohort (p = 0.036).
"We are very excited by the positive Phase 2 results for AP-101," said Angela Genge, MD, Chief Medical Officer of AL-S Pharma (search). "We are observing very consistent results across survival, function, and biomarkers in two independent cohorts within our study. Despite the statistical limitations of a Phase 2 study, the exploratory outcome data indicates that treatment with AP-101 results in a clinically meaningful treatment effect in both sporadic ALS (search) as well as SOD1 (search)-ALS patients."
Functional and Biomarker Improvements
The survival benefits were accompanied by disease stabilization as measured by King's staging. Functional decline measured by ALSFRS-R was reduced in study participants with elevated misfolded SOD1 (search) at baseline and in SOD1 mutation carriers. Additionally, AP-101 treatment resulted in favorable neurofilament biomarker changes that aligned with the observed clinical benefits.
The study design included 52 participants with sporadic ALS (search) and 21 with mutant SOD1 (search)-ALS, treated over six months followed by a six-month open-label extension and safety follow-up period. The trial evaluated safety, tolerability, pharmacodynamic markers, and pharmacokinetics of the investigational therapy.
Targeting Misfolded SOD1 as Disease-Modifying Approach
AP-101 is designed to selectively target misfolded SOD1 (search) to disrupt the progressive spread of pathology in ALS (search). The Phase 2 study results support the hypothesis that targeting misfolded SOD1 represents a disease-modifying approach in ALS treatment. The investigational therapy has received orphan drug designations from the FDA, EMA, and Swissmedic.
"We are deeply committed to advancing an urgently needed new treatment option for ALS (search). Together with our investigators, advisors, collaborators, and their clinical teams, we are pioneering a new disease-modifying approach by targeting misfolded SOD1 (search) with a therapeutic antibody," said Michael Salzmann, PhD, Chief Executive Officer of AL-S Pharma (search).
Advancing to Phase 3 Development
Based on the successful Phase 2 data, AL-S Pharma (search) is currently preparing for a confirmatory Phase 3 clinical study. The company plans to engage with regulators on next steps in the coming months while preparing for the late-stage development program.
AL-S Pharma (search) is a Swiss-based single-asset company founded and co-owned by Neurimmune (search) and TVM Capital Life Science (search), fully financed by TVM Life Science Innovation I and Neurimmune. The company brings together experienced biotech and pharmaceutical leaders with expertise spanning drug discovery, translational research, and clinical development.